Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province.
South Africa
essential medicines
formulary
list (data structure)
management
pharmaceutical and therapeutics committees
rational medicine use
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
04
2020
accepted:
31
07
2020
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
26
9
2020
Statut:
epublish
Résumé
The World Health Organization identified Pharmaceutical and Therapeutics Committees (PTCs) at district and hospital levels as one of the pivotal models to promote rational use of medicines (RUM). This is endorsed by the Government in South Africa. Formulary development and management is one of the main functions of PTCs. This study aimed to describe the formulary management activities among PTCs in public hospitals in Gauteng Province, South Africa, following initiatives to promote RUM in South Africa. Qualitative, nonparticipatory, observational study, observing 26 PTC meetings. Data were coded and categorized using NVivo9 More than half of the observed PTCs reviewed their formulary lists. There was variation in the review process among institutions providing different levels of care. Various aspects were considered for formulary management especially requests for medicines to be added. These included cost considerations (mainly focusing on acquisition costs), evidence-based evaluation of clinical trials, patient safety, clinical experience and changes in the National Essential Medicines List (NEML). The tertiary PTCs mostly dealt with applications for new non-EML medicines, while PTCs in the other hospitals mainly requested removal or addition of EML medicines to the list. This is the first study from Gauteng Province, South Africa, reporting on how decisions are actually taken to include or exclude medicines onto formularies within public sector hospitals providing different levels of care. Various approaches are adopted at different levels of care when adding to- or removing medicines from the formulary lists. Future programs should strengthen PTCs in specialized aspects of formulary management. A more structured approach to formulary review at the local PTC level should be encouraged in line with the national approach when reviewing possible additions to the NEML.
Identifiants
pubmed: 32973508
doi: 10.3389/fphar.2020.01267
pmc: PMC7466677
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1267Informations de copyright
Copyright © 2020 Matlala, Gous, Meyer and Godman.
Références
Basic Clin Pharmacol Toxicol. 2014 Sep;115(3):268-76
pubmed: 24528496
Front Pharmacol. 2014 Jun 17;5:106
pubmed: 24987370
Soc Sci Med. 2007 Nov;65(10):2116-29
pubmed: 17698271
BMC Health Serv Res. 2016 Sep 21;16(1):499
pubmed: 27654857
Hosp Pract (1995). 2020 Mar 14;48(2):51-67
pubmed: 32196395
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:73-8
pubmed: 23640191
Lancet Public Health. 2017 Sep;2(9):e390-e391
pubmed: 29253405
Br J Clin Pharmacol. 2018 Aug;84(8):1659-1667
pubmed: 29349812
PLoS Med. 2010 Oct 19;7(10):e1000352
pubmed: 20976098
Front Pharmacol. 2019 Mar 28;10:279
pubmed: 30983996
S Afr Med J. 2019 Dec 12;110(1):16-20
pubmed: 31865937
Expert Rev Anti Infect Ther. 2019 Jul;17(7):535-546
pubmed: 31257952
Expert Rev Clin Pharmacol. 2018 Dec;11(12):1255-1262
pubmed: 30451035
Expert Rev Clin Pharmacol. 2015 Jan;8(1):77-94
pubmed: 25487078
Eur J Clin Pharmacol. 2018 Jan;74(1):131-138
pubmed: 29063149
Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):264-9
pubmed: 23107106
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:79-87
pubmed: 23640192
Health Policy Plan. 2001 Mar;16(1):13-20
pubmed: 11238425
Eur J Public Health. 2018 Apr 1;28(2):224-230
pubmed: 29165586
P T. 2013 Apr;38(4):213-6
pubmed: 23785226
Lancet. 2008 Dec 20;372(9656):2111; author reply 2111-2
pubmed: 19101382
Front Pharmacol. 2014 Jun 10;5:109
pubmed: 24959145
Basic Clin Pharmacol Toxicol. 2011 Apr;108(4):224-33
pubmed: 21414143
BMC Health Serv Res. 2017 Jan 7;17(1):17
pubmed: 28061899
Med Care. 1990 Oct;28(10):928-42
pubmed: 2232923
Health Policy. 2012 Aug;106(3):225-32
pubmed: 22682762
PLoS One. 2020 Feb 6;15(2):e0228201
pubmed: 32027679
PLoS One. 2009;4(2):e4439
pubmed: 19209224
PLoS Med. 2012;9(5):1-7
pubmed: 22629233
Am J Health Syst Pharm. 1999 Apr 1;56(7):622-8
pubmed: 10423208
Pharmacoeconomics. 2015 Sep;33(9):905-24
pubmed: 26048353
Lancet. 2009 Jan 17;373(9659):240-9
pubmed: 19042012
BMJ Open. 2013 Jun 20;3(6):
pubmed: 23794552
Lancet. 2017 Jan 28;389(10067):403-476
pubmed: 27832874
BMJ Open. 2017 May 2;7(4):e014345
pubmed: 28465306
Drug Saf. 2012 Jan;35 Suppl 1:73-87
pubmed: 23446788
Expert Opin Drug Saf. 2018 Jul;17(7):681-695
pubmed: 29952667
Front Pharmacol. 2017 Oct 05;8:674
pubmed: 29056910
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):655-666
pubmed: 30014725
Pharm World Sci. 2010 Dec;32(6):767-75
pubmed: 20820918
Front Pharmacol. 2017 Nov 09;8:751
pubmed: 29163151
Ann Rheum Dis. 2014 Jan;73(1):198-206
pubmed: 23467636
Front Pharmacol. 2013 May 14;4:39
pubmed: 23717279
Health Policy. 2008 May;86(2-3):129-41
pubmed: 18192059
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):439-41
pubmed: 22971029
Lancet Public Health. 2017 Sep;2(9):e411-e419
pubmed: 29253412
J Pharm Policy Pract. 2016 Feb 24;9:6
pubmed: 26913200
Pharmacy (Basel). 2016 Oct 28;4(4):
pubmed: 28970408
Am J Health Syst Pharm. 2008 Jul 1;65(13):1272-83
pubmed: 18589893
Pharm Pract (Granada). 2019 Oct-Dec;17(4):1590
pubmed: 31897253
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1273-1280
pubmed: 28776442
J Clin Pharm Ther. 2016 Feb;41(1):64-9
pubmed: 26778812
Pharmacoeconomics. 1992 May;1(5):377-82
pubmed: 10147002
Health Policy. 2003 Dec;66(3):295-303
pubmed: 14637013
Int J Clin Pharm. 2011 Jun;33(3):475-83
pubmed: 21416393
Soc Sci Med. 2004 May;58(9):1757-66
pubmed: 14990376
Int J Clin Pract. 2009 Sep;63(9):1320-6
pubmed: 19691615
Front Pharmacol. 2020 Mar 20;11:108
pubmed: 32265688
Expert Rev Clin Pharmacol. 2019 Feb;12(2):159-168
pubmed: 30407089
Hosp Pract (1995). 2018 Apr;46(2):77-87
pubmed: 29426263
Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755-8
pubmed: 26368060
South Med Rev. 2012 Dec;5(2):3-8
pubmed: 23535994
Antibiotics (Basel). 2019 Dec 20;9(1):
pubmed: 31861923
Front Pharmacol. 2014 Oct 08;5:219
pubmed: 25339902